Product Description: Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF). Tisotumab vedotin consists of a fully human monoclonal antibody to tissue factor (TF-011) conjugated to Monomethyl Auristatin E (MMAE). Tisotumab vedotin has good antitumor activity and can be used in the research of advanced or metastatic solid tumors[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Markham A, et al. Tisotumab Vedotin: First Approval. Drugs. 2021 Dec;81(18):2141-2147.